Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE +/- Irinotecan in Relapsed/Refractory Colorectal Carcinoma
NCT00051987Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2002
- Primary completion
- Mar 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in colorectal carcinoma (CRC) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Objective Tumor Response. Started Dec 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00051987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051987.